We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Optimata Granted Patent for Granulopoiesis-Modelling System
News

Optimata Granted Patent for Granulopoiesis-Modelling System

Optimata Granted Patent for Granulopoiesis-Modelling System
News

Optimata Granted Patent for Granulopoiesis-Modelling System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Optimata Granted Patent for Granulopoiesis-Modelling System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Optimata Ltd. announced that it has been granted U.S. Patent 7,266,483 for a system and method that models granulopoiesis and that can optimize drug therapies in order to reduce or prevent neutropenia. Neutropenia is a shortage of neutrophils in the blood and a toxic condition that often occurs during chemotherapy.

Optimata’s technology comprises a computerized biosimulation system and a computer-implemented method for optimizing drug therapies that affect neutropenia. The patent covers optimization methods and systems applied to both individual and patient populations.

The technology can predict the impact of drug regimens on neutrophil levels in the blood and can be applied to optimize the development of new drug therapies (both monotherapy and combination therapy) so as to alleviate their myelotoxicity; to optimize the development of supportive drug treatments; and to repurpose existing drugs whose use or development has been limited or discontinued because of toxic side effects.

“This patent joins our previously-granted patent for optimizing the development of thrombocytopenia-affecting drugs and reinforces Optimata's leadership position in the field of predictive toxicity,” said Guy Malchi, CEO of Optimata.

“By using the integrated predictive powers of Optimata's Virtual Patient Engine, Optimata and its drug development partners have the benefit of an 'early warning system' for two of the leading toxic consequences of oncological drug failure – neutropenia and thrombocytopenia.”

Advertisement